|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Asymptomatic profound sinus brady- cardia (heart rate 45 ) in non-small cell lung cancer patients trea- ted with crizotitfib显示文摘 | Ou SH Azada M Dy J | 2011 | J Thorac Oncol2011，6，12： | 1 |
| 2 | Prognostic factors for survival in ex?tensive stage small cell lung cancer (ED-SCLC) : the importance of smoking history, socioeconomic and marital statuses, and eth?nicity显示文摘 | Ou SH Ziogas A Zell lA | 2009 | J Thorac Oncol2009，4，1： | 1 |
| 3 | Radiation necrosis presenting as pseudoprogression (PsP)during Alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management显示文摘 | Ou SH Klempner SJ Azada MC | 2015 | Lung Cancer2015，88，3： | 1 |
| 4 | ROS1 rearrangements define a u-nique molecular class of lung cancers显示文摘 | Bergethon K Shaw AT Ou SH | | 0，，： | 1 |
| 5 | Next-genera- tion sequencing reveals a novel NSCLC ALK Fl174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib ( CH5424802/RO5424802 ) in ALK-rearranged NSCLC patients who progressed on crizotinib 显示文摘 | IGNATIUS Ou SH AZADA M HSIANG DJ | 2014 | J Thorac 0n- col2014，9，4： | 1 |
| 6 | Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673) 显示文摘 | Ou SH AhnJS Petris LDj | 2015 | J Clin Oncol2015，33，： | 1 |
| 7 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases显示文摘 | Costa DB Shaw AT Ou SH | 2015 | J Clin Oncol2015，33，17： | 1 |
| 8 | ROS1 rearrangements define a unique molecular class of lung cancers显示文摘 | Bergethon K Shaw AT Ou SH | 2012 | J Clin Oncol2012，30，： | 1 |
| 9 | Efficacy and safety of cr-izotinib in patients with advanced c-Met-amplified non-small celllung cancer ( NSCLC ) 显示文摘 | Camidge DR Ou SH Shapiro G | 2014 | J Clin Oncol2014，32，5： | 1 |
| 10 | Molecular characteristics of occult hepatitis B virus from blood donors in southeast China显示文摘 | Yuan Q Ou SH Chen CR | | 0，，： | 1 |
| 11 | ROS1 as a fdruggable' receptortyrosine kinase : lessons learned from inhibiting the ALKpathway 显示文摘 | Ou SH Tan J Yen Y | 2012 | Expert Rev Anticancer Ther2012，12，4： | 1 |
| 12 | ALK rearrange- ments are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer显示文摘 | Gainor JF Varghese AM Ou SH | 2013 | Clin Cancer Res2013，19，15： | 1 |
| 13 | Prognostic factors for survival in extensivestage small cell lung cancer(ED-SCLC):the importance of smoking history,socioeconomic and marital,and ethnicity显示文摘 | Ou SH Ziogas A Zell JA | 2009 | Thorac Oncol2009，4，1： | 1 |
| 14 | ROS1 rearran- gements define a unique molecular class of lung cancers 显示文摘 | Bergethon K Shaw AT Ou SH | 2012 | J Clin Oncol2012，30，8： | 1 |
| 15 | Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer:results from a phase Ⅱ study显示文摘 | Schiller JH Larson T Ou SH | | 0，，23： | 1 |
| 16 | Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC):the importance of smoking history,socioeconomic and marital statuses,and ethnicity显示文摘 | Ou SH Ziogas A Zell JA | 2009 | J Thorac Oncol2009，4，1： | 1 |
| 17 | Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastie lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification 显示文摘 | Ou SH Kwak EL Siwak-Tapp C | 2011 | J Thorac Oncol2011，6，5： | 1 |
| 18 | Selective inhibition of early-but not late-expressed HIF-1α is neuroprotective in rats after focal ischemic brain damage显示文摘 | Yeh SH Ou LC Gean PW | | 0，，： | 1 |
| 19 | Late expression of brain-derived neurotrophic factor in the amygdala is required for persistence of fear memory显示文摘 | Ou LC Yeh SH Gean PW | 2010 | Neurobiol Learn Mem2010，93，3： | 1 |
| 20 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases 显示文摘 | COSTA DB SHAW AT OU SH | 2015 | J Clin Oncol2015，33，17： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员